Table 1.
Pattern of mtDNA mutation in the UCC patients and corresponding urine sediments.
| Patient ID1 |
Number of mtDNA mutation in Tumor/position |
Number of mtDNA mutation in Urine2/Potition |
Stage | Grade |
|---|---|---|---|---|
| UCC3 | 1/A950G | 1/A950G | Ta | III |
| UCC4 | 1/G1606A | 1/G1606A | Ta | III |
| UCC9 | 1/A2644G | 1/A2644G | Ta | III |
| UCC12 | 0 | 0 | Ta | II |
| UCC13 | 1/A2707G | 1/A2707G | Ta | II |
| UCC17 | 1/T3590C | 1/T3590C | Ta | II |
| UCC21 | 0 | 0 | Ta | II |
| UCC24 | 0 | 0 | Ta | II |
| UCC25 | 0 | 0 | Ta | II |
| UCC28 | 0 | 0 | Ta | II |
| UCC1 | 1/A3755C | 1/A3755C | T1 | II |
| UCC5 | 1/C4493T | 1/C4493T | T1 | II |
| UCC7 | 1/A5257G | 1/A5257G | T1 | II |
| UCC10 | 2/T6459C; T6562C | 2/T6459C; T6562C | T1 | II |
| UCC15 | 0 | 0 | T1 | III |
| UCC18 | 0 | 0 | T1 | II |
| UCC20 | 2/C2544T; A3011C | 0 | T1 | II |
| UCC22 | 0 | 0 | T1 | III |
| UCC2 | 1/G8833A | 1/G8833A | T2 | II |
| UCC6 | 1/A9604G | 1/A9604G | T2 | III |
| UCC8 | 0 | 0 | T2 | III |
| UCC11 | 3/G9655A; C11300T; A4337G | 2/G9655A; C11300T; | T2 | III |
| UCC14 | 0 | 0 | T2 | III |
| UCC16 | 1/A14469G | 1/A14469G | T2 | III |
| UCC19 | 1/T14787C | 1/T14787C | T2 | II |
| UCC23 | 0 | 0 | T2 | II |
| UCC26 | 1/C15329T | 1/C15329T | T2 | II |
| UCC27 | 2/G5619A; A14706G | 0 | T2 | III |
| UCC29 | 1/T15722C | 1/T15722C | T2 | III |
| UCC30 | 1/C5317T | 1/C5317T | T2 | II |
| UCC31 | 1/T12083C | 1/T12083C | T2 | III |
1
UCC: Urothelial cell carcinoma;
2
MtDNA was isolated from matched urine sediment of the UCC patients and sequenced on the Affymetrix Mitochip v2.0 sequencing array platform along with the corresponding tumor and lymphocytes.